Rosuvastatin Calcium Cas:147098-20-2

We are Rosuvastatin Calcium CAS:147098-20-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Description:

Product Name: Rosuvastatin Calcium CAS NO: 147098-20-2

 

Synonyms:

(3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic Acid Calcium Salt;

Rosuvastatin Calcium Salt;

Rosuvastatin Hemicalcium;

 

Chemical & Physical Properties:

Appearance: White to off-white crystalline Solid

Assay :≥99.00%

Boiling Point: 745.6℃ at 760 mmHg

Melting Point: 122℃

Flash Point: 404.7℃

Storage condition: -20℃ Freezer

 

Safety Information:

HS Code: 2935009090

 

Rosuvastatin Calcium Salt is a selective, competitive HMG-CoA reductase inhibitor.

Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM. IC50 Value: 11 nM Target: HMG-CoA reductasein vitro: Rosuvastatin is relatively hydrophilic and is highly selective for hepatic cells; its uptake is mediated by the liver-specific organic anion transporter OATP-C. Rosuvastatin is a high-affinity substrate for OATP-C with apparent association constant of 8.5 μM. Rosuvastatin inhibits cholesterol biosynthesis in rat liver isolated hepatocytes with IC50 of 1.12 nM. Rosuvastatin causes approximately 10 times greater increase of mRNA of LDL receptors than pravastatin [1]. Rosuvastatin (100 μM) decreases the extent of U937 adhesion to TNF-α-stimulated HUVEC. Rosuvastatin inhibits the expressions of ICAM-1, MCP-1, IL-8, IL-6, and COX-2 mRNA and protein levels through inhibition of c-Jun N-terminal kinase and nuclear factor-kB in endothelial cells.in vivo: Rosuvastatin (3 mg/kg) daily administration for 14 days decreases plasma cholesterol levels by 26% in male beagle dogs with normal cholesterol levels. In cynomolgus monkeys, Rosuvastatin decreases plasma cholesterol levels by 22%. Rosuvastatin (20 mg/kg/day) administration for 2 weeks, significantly reduces very low-density lipoproteins (VLDL) in diabetes mellitus rats induced by Streptozocin. Rosuvastatin shows antiatherothromhotic effects in vivo. Rosuvastatin (1.25 mg/kg) significantly inhibits thrombin-induced transmigration of monocvtes across mesenteric venules via inhibition of the endothelial cell surface expression of P-selectin, and increases the basal rate of nitric oxide in aortic segments by 2-fold times .

 

If you are interested in our products or have any questions, please feel free to contact us!

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.

Related Products:2-acetyl-4-tert-butylcyclohexan-1-one manufacturer | 2-butyl-2-propan-2-ylpropane-1,3-diol supplier | isopropyl (3Z)-6-O-acetyl-3-deoxy-4-S-ethyl-3-[(methylthio)methylene]-4-thio-α-D-threo-hexopyranosid-2-ulose producer.